Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5872067 | 0.77 | MAPT (0.40) | MAPTNPSR1LMNASMN1; SMN2HPGD | |
| SCHEMBL5871437 | 0.77 | MAPT (0.40) | MAPTNPSR1LMNASMN1; SMN2HPGD | |
| SCHEMBL5871857 | 0.77 | MAPT (0.40) | MAPTNPSR1LMNASMN1; SMN2HPGD | |
| SCHEMBL23668754 | 0.76 | MAPT (0.39) | MAPTNPSR1LMNASMN1; SMN2HPGD | |
| SCHEMBL5871896 | 0.76 | MAPT (0.42) | MAPTNPSR1HPGDMEN1KMT2A | |
| SCHEMBL77732 | 0.74 | MEN1 (0.63) | MAPTNPSR1HPGDMEN1KMT2A | |
| SCHEMBL5871916 | 0.72 | CFTR (0.38) | MAPTLMNAHPGD | |
| SCHEMBL482817 | 0.71 | ALDH1A1 (0.30) | — | |
| SCHEMBL3430755 | 0.69 | MEN1 (0.58) | MAPTNPSR1MEN1KMT2A | |
| SCHEMBL15913317 | 0.69 | MAPT (0.46) | MAPTNPSR1LMNASMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1266151-C | Naphthyridine derivatives | OTSUKA PHARMA CO LTD (JP) | 2006-07-26 | — | — | CN | disclosed |
| US-7071187-B2 | Naphthyridine derivatives | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2006-07-04 | — | — | US | disclosed |
| CN-1547581-A | Naphthyridine derivatives | 株式会社大V制药工场 | 2004-11-17 | — | — | CN | disclosed |
| US-20040214853-A1 | Naphthyridine derivatives | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2004-10-28 | — | — | US | disclosed |
| EP-1426374-A1 | NAPHTHYRIDINE DERIVATIVE | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2004-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214853-A1 | Naphthyridine derivatives | MT-ND1, OPRD1, NR0B1 | MAPT 2184/4885NPSR1 135/4885LMNA 2666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.